Skip to content

US · LGVN · BIOTECHNOLOGY

Longeveron Inc. (LGVN) intrinsic value and stock valuation

$1.66as of 2026-11-21 · Mkt cap 15.27M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Longeveron Inc. DCF and intrinsic value

InvestorsCraft values LGVN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from LGVN’s statements →

Longeveron Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miami, FL 33136 longeveron.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$1.2M-26.6% 5y CAGRd
20182025
Net income
-$-22.7M
20182025
Free cash flow
-$-18.89M
20182025
Total equity
$5.67M+23.7% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$1.2M$2.39M$710K$1.22M$1.31M
Operating income-$-23.29M-$-16.52M-$-21.03M-$-18.04M-$-17.46M
Net income-$-22.7M-$-15.97M-$-21.41M-$-18.84M-$-17.05M
EPSd-$-1.29M-$-1.07M-$-9.87M-$-8.97M-$-9.02M
Operating cash flow-$-18.64M-$-13.87M-$-19M-$-13.97M-$-9.64M
Capital expenditure-$-240K-$-990K-$-300K-$-860K-$-1.31M
Free cash flow-$-18.89M-$-14.86M-$-19.3M-$-14.82M-$-10.95M
Total assets$10.3M$25.6M$12.1M$27.4M$42.8M
Total debt$820K$1.45M$2.04M$2.6M$3.14M
Net debt-$-3.84M-$-17.79M-$-2.91M-$-7.9M-$-22.52M
Total equity$5.67M$21.9M$6.74M$20.5M$37.5M
Cash and short-term investments$4.66M$19.2M$5.36M$19.7M$35M
Income statement
20252024202320222021
Revenue$1.2M$2.39M$710K$1.22M$1.31M
Cost of revenue$400K$510K$490K$720K$720K
Gross profit$800K$1.88M$220K$500K$590K
Research and development expenses$12M$8.14M$9.07M$9.37M$7.09M
Selling, general and administrative expenses$12.1M$10.3M$12.2M$9.17M$11M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$24.1M$18.4M$21.3M$18.5M$18.1M
Cost and expenses$24.5M$18.9M$21.7M$19.3M$18.8M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.23M$960K$950K$890K$910K
Ebitda-$-21.48M-$-15.02M-$-20.47M-$-17.94M-$-16.13M
Operating income-$-23.29M-$-16.52M-$-21.03M-$-18.04M-$-17.46M
Total other income/expenses, net$580K$550K-$-380K-$-790K$410K
Income before tax-$-22.7M-$-15.97M-$-21.41M-$-18.84M-$-17.05M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-22.7M-$-15.97M-$-21.41M-$-18.84M-$-17.05M
Weighted average shares outstanding$17.6M$14.9M$2.17M$2.1M$1.89M
Weighted average diluted shares outstanding$17.6M$14.9M$2.17M$2.1M$1.89M
Balance sheet
20252024202320222021
Cash and short-term investments$4.66M$19.2M$5.36M$19.7M$35M
Net receivables$100K$80K$110K$220K$60K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.45M$19.6M$5.85M$20.3M$35.4M
Property, plant and equipment, net$2.35M$3.33M$3.75M$4.48M$4.88M
Goodwill and intangible assets$2.29M$2.4M$2.29M$2.41M$2.33M
Long-term investments$100K$0.00$0.00$0.00$0.00
Total non-current assets$4.81M$5.93M$6.23M$7.13M$7.39M
Total assets$10.3M$25.6M$12.1M$27.4M$42.8M
Accounts payable$420K$100K$640K$1.75M$650K
Short-term debt$660K$620K$590K$560K$540K
Deferred revenue$40K$40K$510K$510K$200K
Total current liabilities$4.09M$2.58M$3.89M$4.87M$2.71M
Long-term debt$170K$820K$1.45M$2.04M$2.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$500K$1.09M$1.45M$2.04M$2.6M
Capital lease obligations$170K$1.45M$2.04M$2.6M$3.14M
Total liabilities$4.59M$3.67M$5.34M$6.91M$5.31M
Common stock$20K$10K$0.00$20K$20K
Retained earnings-$-132.31M-$-109.61M-$-84.98M-$-62.77M-$-43.94M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-360K$0.00
Total equity$5.67M$21.9M$6.74M$20.5M$37.5M
Total investments$100K$0.00$410K$9.15M$9.38M
Total debt$820K$1.45M$2.04M$2.6M$3.14M
Net debt-$-3.84M-$-17.79M-$-2.91M-$-7.9M-$-22.52M
Cash flow statement
20252024202320222021
Net income-$-22.7M-$-15.97M-$-21.41M-$-18.84M-$-17.05M
Depreciation and amortization$1.23M$960K$950K$890K$910K
Stock-based compensation$1.68M$2.33M$2.03M$2.17M$7.74M
Change in working capital$1.06M-$-1.24M$40K$240K-$-1.09M
Accounts receivable-$-20K$30K$110K-$-160K$370K
Inventory$0.00$0.00$0.00$0.00-$-370K
Accounts payable$330K-$-540K$0.00$1.11M-$-940K
Net cash provided by operating activities-$-18.64M-$-13.87M-$-19M-$-13.97M-$-9.64M
Investments in property, plant and equipment-$-590K-$-990K-$-300K-$-860K-$-1.31M
Acquisitions, net$0.00$0.00$0.00$0.00$90K
Net cash used for investing activities-$-590K-$-640K$8.19M-$-680K-$-10.7M
Common stock issued$4.98M$12.9M$0.00$0.00$45.8M
Common stock repurchased$0.00$0.00-$-170K$0.00$0.00
Dividends paid$0.00-$-8.65M$0.00$0.00$0.00
Net cash used for financing activities$4.67M$28.8M$5.26M-$-510K$45.2M
Net change in cash-$-14.57M$14.3M-$-5.55M-$-15.15M$24.8M
Cash at end of period$4.66M$19.2M$4.95M$10.5M$25.7M
Operating cash flow-$-18.64M-$-13.87M-$-19M-$-13.97M-$-9.64M
Capital expenditure-$-240K-$-990K-$-300K-$-860K-$-1.31M
Free cash flow-$-18.89M-$-14.86M-$-19.3M-$-14.82M-$-10.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Longeveron Inc.

        Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

        CEO
        Stephen H. Willard
        Employees
        38
        Beta
        -0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Longeveron Inc. (LGVN)?

        Longeveron Inc. (LGVN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LGVN undervalued?

        LGVN trades at a price of $1.66 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.